

U.S.S.N: 09/464,377
Attorney Docket No: 13761-0726-US1
Client Docket No: 2804

C1 *entire* about 85% sequence identity to SEQ ID NO:1 or a complementary sequence thereof, wherein the nucleic acid encodes a polypeptide that binds a C terminus of GRIP1.

C2 39. (Amended) The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule encodes a polypeptide comprising SEQ ID NO:2.

C3 42. (Amended) The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a sequence that has at least about 90% sequence identity to SEQ ID NO:1.

C4 45. (Amended) The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a sequence that has at least about 95% sequence identity to SEQ ID NO:1.

48. (New) The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises SEQ ID NO:1.

49. (New) A recombinant vector comprising the nucleic acid molecule of claim 45.

50. (New) A genetically engineered cell comprising the recombinant vector of claim 46.

C5 51. (New) The isolated nucleic acid molecule of claim 1, wherein the polypeptide comprises methyltransferase activity.

52. (New) The isolated nucleic acid molecule of claim 1, wherein the polypeptide comprises coactivator activity.

REMARKS

STATUS OF THE CLAIMS

Claims 1-47 were pending in this application. Claims 4-38 have been cancelled without prejudice, having been withdrawn from consideration due to election after a restriction requirement. Claims 1, 39, 42, 45 have been amended. New claims 48-52 have been added herein. A marked up version of the amended claims is provided in Appendix I. Following entry of the amendments claims 1-3 and 39-52 will be pending and at issue. A clean copy of all claims